# Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches

**Authors:** Francisco Navarrete, Marta Marín-Mayor, Lorena Martínez-Hostyn, Gabriel Rubio, Jorge Manzanares

PMC · DOI: 10.3390/ijms27031430 · International Journal of Molecular Sciences · 2026-01-31

## TL;DR

This paper reviews benzodiazepine use, their effects on the brain, risks of dependence, and strategies for prevention and treatment.

## Contribution

The paper compiles recent literature to summarize the pharmacology, mechanisms, and management of benzodiazepine dependence.

## Key findings

- Prolonged benzodiazepine use leads to tolerance and dependence via GABAA receptor downregulation and glutamatergic sensitization.
- Effective treatment involves psychological support, substitution with long-acting benzodiazepines, and gradual dose reduction.
- Preventive strategies include short-term prescriptions, minimal dosing, and alternative medications like SSRIs/SNRIs.

## Abstract

Benzodiazepines (BZDs) are globally prevalent psychotropic substances valued for their anxiolytic, hypnotic, anticonvulsant, and myorelaxant properties. Pharmacologically, they act as positive allosteric modulators of the ionotropic GABAA receptor, enhancing inhibitory synaptic transmission. However, prolonged use poses a significant public health concern, risking adverse effects such as cognitive impairment, motor incoordination, tolerance, and physical dependence. The development of tolerance is mediated by complex neurobiological changes, notably the downregulation of GABAA receptor subunits and a compensatory sensitization of excitatory glutamatergic systems. Effective management of established dependence requires comprehensive psychological intervention coupled with pharmacological substitution (switching to a long-acting BZD) and gradual dose tapering. Preventive measures are complex, emphasizing short-term prescriptions, minimum effective dosing, and selecting non-pharmacological or alternative pharmacological agents, such as SSRIs/SNRIs, to mitigate the risk of developing tolerance and dependence. This expert review aims to compile the most relevant, representative, and recent literature summarizing the pharmacology, clinical indications, adverse effects, misuse, and abuse of BZDs that ultimately lead to BZD use disorder (BUD). It also details the involved neurobiological mechanisms and discusses critical preventive and therapeutic strategies, providing readers with the main aspects to consider for addressing this global public health problem.

## Linked entities

- **Proteins:** Rdl (Resistant to dieldrin)

## Full-text entities

- **Diseases:** cognitive impairment (MESH:D003072), motor incoordination (MESH:D002524)
- **Chemicals:** BUD (-), BZD (MESH:D001569)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12898709/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12898709/full.md

## References

182 references — full list in the complete paper: https://tomesphere.com/paper/PMC12898709/full.md

---
Source: https://tomesphere.com/paper/PMC12898709